Pfizer Target of Unusually Large Options Trading (PFE)
Shares of Pfizer (NYSE:PFE) was the recipient of some unusual options trading activity on Thursday. Investors bought 16,268 put options on the stock, Analyst RN reports. This represents an increase of 118% compared to the typical daily volume of 7,470 put options.
A number of analysts have recently weighed in on PFE shares. Analysts at Jefferies Group reiterated a “hold” rating on shares of Pfizer in a research note to investors on Friday, October 11th. Separately, analysts at Credit Suisse initiated coverage on shares of Pfizer in a research note to investors on Tuesday, October 8th. They set an “outperform” rating and a $34.00 price target on the stock. Finally, analysts at JPMorgan Chase & Co. raised their price target on shares of Pfizer from $33.00 to $34.00 in a research note to investors on Friday, September 27th. They now have an “overweight” rating on the stock. Two analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating to the company’s stock. Pfizer presently has a consensus rating of “Buy” and a consensus price target of $30.92.
Shares of Pfizer (NYSE:PFE) traded up 1.54% during mid-day trading on Thursday, hitting $30.26. The stock had a trading volume of 29,711,652 shares. Pfizer has a 1-year low of $23.55 and a 1-year high of $31.15. The stock’s 50-day moving average is $28.70 and its 200-day moving average is $28.77. The company has a market cap of $200.3 billion and a price-to-earnings ratio of 8.27.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 30th. The company reported $0.56 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.55 by $0.01. The company had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $13.02 billion. During the same quarter last year, the company posted $0.62 earnings per share. Pfizer’s revenue was down 7.1% compared to the same quarter last year. Analysts expect that Pfizer will post $2.16 EPS for the current fiscal year.
Pfizer Inc (NYSE:PFE) is a research-based, global biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.